Cancer, Advanced Clinical Trial
Official title:
A Histology-Independent Study of the Cyclin Inhibitor Palbociclib in Patients With Advanced Cancer Harboring Aberrations in the Cyclin Pathway
The investigational drug being tested in this study is palbociclib. Palbociclib is considered experimental because it is not approved by the FDA for the treatment of all cancers. Palbociclib is currently approved for use in breast cancer. Palbociclib is a drug belonging to a family of drugs called kinase inhibitors. These drugs slow or stop the activity of particular proteins involved in the growth of human cells and in the abnormal growth of cancer cells. Blocking these proteins may decrease or stop tumor growth. The purpose of this study is to assess the safety of the study drug, to see how well it is tolerated, and also to find a safe dose range of the study drug in patients with specific kinds of tumor genetic changes.
This study proposes to give the cyclin dependent kinase (CDK) inhibitor palbociclib to patients with advanced malignancy harboring cyclin pathway aberrations (CCN/CDK alterations). The investigators study will determine whether cyclin signaling aberrations associate with response to this CDK inhibitor. Once completed, this study will identify subpopulations of patients that would best benefit from CDK inhibitor therapy with palbociclib and suggest directions for future study. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04604873 -
The Integrated Support and Palliative in Cancer Day-care Hospital for Patients With Advanced Cancers: Impact on Quality of Life, Care Pathways and Support for Caregivers (HDJ-SPI)
|
N/A | |
| Completed |
NCT00750178 -
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK0683 in Patients With Advanced Cancer (0683-008)
|
Phase 1 | |
| Recruiting |
NCT04028479 -
The Registry of Oncology Outcomes Associated With Testing and Treatment
|
||
| Recruiting |
NCT05200572 -
Study of a Behavioral Intervention for Older Advanced Cancer Patients and Their Caregivers
|
N/A | |
| Recruiting |
NCT03896958 -
The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
|
||
| Recruiting |
NCT03383094 -
Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT03763396 -
Azoles Targeting Recurrent High Grade Gliomas
|
Early Phase 1 | |
| Completed |
NCT01380184 -
Pharmacokinetics of Ridaforolimus (MK-8669) in Chinese Participants (MK-8669-059)
|
Phase 1 | |
| Recruiting |
NCT03452774 -
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
|